Skip to main content
Fachgebiete
Automobil + Motoren Bauwesen + Immobilien Business IT + Informatik Elektrotechnik + Elektronik Energie + Nachhaltigkeit Finance + Banking Management + Führung Marketing + Vertrieb Maschinenbau + Werkstoffe Versicherung + Risiko
DE
EN
Themenseiten
Organisationspsychologie Projektmanagement Marketing Smart Manufacturing
Bücher
Zeitschriften
Weitere Formate
Podcasts Webinare Technik Webinare Wirtschaft Kongresse Veranstaltungskalender Awards
Jetzt Einzelzugang starten
Zugang für Unternehmen
Referenzkunden
MTZ-Fachkongress

Antriebe und Energiesysteme von morgen


Austausch von Automobil- und Energiewirtschaft

Am 14./15. Mai geht es in Chemnitz um die Mobilitätswende durch Elektro- und Wasserstofffahrzeuge.
Erweiterte Suche
Anmelden
nach oben
Erschienen in:
Buchtitelbild

2018 | OriginalPaper | Buchkapitel

Case I: 3DMed: An R&D Platform for Personalised Precision Anti-cancer Drugs

verfasst von : Xiaoming Zhu

Erschienen in: China's Technology Innovators

Verlag: Springer Singapore

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

In 2010, Xiong Lei, a Ph.D. graduate from the Institute of Biochemistry and Cell Biology, SIBCB, CAS, left his post-doctoral research in the University of Zurich to found 3DMed with five other senior professionals, aiming to substantially improve R&D efficiency and approval rates of anti-cancer drugs and deliver highly effective clinical treatment for cancer. The new company is headquartered in the Shanghai Caohejing Hi-Tech Park, where over 140 biomedical start-ups are planning their business roadmaps. The question now is how 3DMed, which had completed two rounds of financing by May 2014, will achieve the expected performance and leverage talent, marketing and capital management, as well as strategic planning, to address the challenges it faces in the early stage of business development as well as to minimise innovation risks in an emerging industry.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Jetzt informieren
Nächstes Kapitel Case II: Micro Platform, Major Innovation—WeChat-Based Ecosystem of Innovation
Fußnoten
1
Jemal et al. [1].
 
2
Chen [2].
 
3
American Cancer Society [3].
 
4
DeSantis et al. [4].
 
5
Berkrot [5].
 
6
Pammolli et al. [6].
 
7
Mao and Chen [7].
 
8
Lu et al. [8].
 
9
Moffat et al. [9].
 
10
Deng [10].
 
11
U.S. Food and Drug Administration, “The Drug Development Process” (24 June 2015), FDA, http://​www.​fda.​gov/​forpatients/​approvals/​drugs/​default.​htm, last accessed on 27 October 2015.
 
12
Roche [11].
 
13
Paul et al. [12].
 
14
IMS Institute, “Global Oncology Trend Report: Innovation in Cancer Care and Implications for Health Systems”, IMS Reports, May 2014.
 
15
Wang [13].
 
16
Li [14].
 
17
“R&D Investment by U.S. Biopharmaceutical Companies Reached Record Levels in 2010”, PhRMA, 15 March 2011.
 
18
CFDA Southern Medicine Economic Research Institute: Blue Book on Chinese Pharmaceutical Market Development 2010, 29 October 2010.
 
19
Shi [15].
 
20
Yu [16]
 
21
Zhu [17].
 
22
Yang [18].
 
23
Xu [19].
 
24
Liu [20].
 
25
Wang [21].
 
26
[US] Naisbitt [22].
 
27
Chen [23], Zhou and Liu [24].
 
28
Wang and Baorui [25].
 
29
“2003 Release: International Consortium Completes HGP”, National Human Genome Research Institute, 14 April 2003.
 
30
Luo [26], Sun et al. [27].
 
31
Calvo et al. [28].
 
32
Sherman et al. [29], Subramanian et al. [30].
 
33
“2003 Release: International Consortium Completes HGP”, National Human Genome Research Institute, 14 April 2003.
 
34
Gangwar and Worabo [31].
 
35
McLeod and Evans [32].
 
36
Han and Yang [33].
 
37
Liu [34], Herper [35].
 
38
Sharma et al. [36].
 
39
Wang and Wang [37].
 
Literatur
1.
Jemal A, Bray F, Center MM et al (2011) Global Cancer Statistics. Oncol Radiother (Feb)
2.
Chen W. Chinese Cancer Registry Annual Report 2013, Chinese Cancer Registry Center, 14 Apr 2014
3.
American Cancer Society (2010) Cancer facts & figures 2010. American Cancer Society, Atlanta
4.
DeSantis CE et al (2014) Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64:252–271CrossRef
5.
Berkrot B (2011) Success rates for experimental drugs falls: study. Reuters (14 February)
6.
Pammolli F, Magazzini L, Riccaboni M (2011) The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discovery 10
7.
Mao K, Chen D. The history of anti-cancer drug R&D. Shanghai Technology Inquiry and Consulting Center, CAS, 22 Feb 2012
8.
Lu Y, Chen D, Xiong Y (2012) Analysis of R&D situation of anti-cancer drugs. Chin Bull Life Sci 6
9.
Moffat JG, Rudolph J, Bailey D (2014) Phenotypic screening in cancer drug discovery—past, present and future. Nat Rev Drug Discovery 13:588–602CrossRef
10.
Deng Z (2013) Overview of new drug development process. Sci Monthly 2
11.
Roche. From Idea to Medicine—Drug Development at Roche. Roche Global, 2 Jan 2013
12.
Paul SM et al (2010) How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discovery (March)
13.
Wang B. Research on competitive strength of Chinese Biopharmaceutical Industry, 2010 edition published by Shanghai University of Finance & Economics Press
14.
Li P. Identifying Future Competitive Trends from Global Anti-Cancer Drug Sales Ranking. Global Oncology Express, April 2014-110
15.
Shi J. AstraZeneca Opens an Innovation Centre with Huge Investment. Xinmin Evening News, 23 Mar 2007
16.
Yu D. Roche Launches China’s First Comprehensive Clinical Trial Centre. The Economic Observer, 31 Oct 2007
17.
Zhu Q (2009) Lilly’s Unique R&D System. CEIBS Bus Rev 7
18.
Yang J. Johnson & Johnson Establishes an R&D Centre in Shanghai as Its Asia Pacific R&D Headquarters. Science and Technology Daily, 23 Apr 2009
19.
Xu H. Novartis Invests USD 1 Billion to establish China’s largest drug R&D centre. Economic Daily, 24 Nov 2009
20.
Liu C. Ding Jian: Chinese pharmaceutical companies lack anti-cancer drug R&D capability. China Science Daily, 12 June 2012
21.
Wang J. Branded drugs perform better than generic drugs. Wen Wei Po, 30 Apr 2014
22.
Naisbitt J (2009) China’s megatrends (trans: Wei P). China Industry & Commerce Associated Press in 2009
23.
Chen S (2013) Somatic mutation and novel strategies for personalized targeting therapy. J Zhejiang Univ 42(1)
24.
Zhou H, Liu J (2011) Gene targeting tailored therapy for the anti-tumor drugs. Anti-Tumor Pharm 1
25.
Wang K, Liu B (2012) Truly personalized medicine to combat cancer. Medicine & Philosophy (Clinical Decision Making Forum Edition) 6
26.
Luo B (2003) Application progress of pharmacogenomics. Chin J Pract Med 19
27.
Sun H, Ouyang W, Sun J (2004) Trend in research of pharmacogenomics in foreign countries. Chin J New Drugs 3
28.
Calvo KR, Liotta LA, Petricoin EF (2005) Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy. Biosci Rep 25(1–2)
29.
Sherman RE et al (2013) Expediting drug development—the FDA’s new ‘breakthrough therapy’ designation. N Engl J Med 369:1877–1880 (14 Nov)
30.
Subramanian R, Sheppard T, Rubin B, Kramer C (2013) FDA’s new breakthrough therapy designation: what does it mean for pricing and market access? OBR Green, Sept 2013, vol 7 (8)
31.
Gangwar SK, Worabo B (2011) Amazing facts about human DNA and genome. Society for Science and Nature, 20 Sept 2011
32.
McLeod HL, Evans WE (2001) Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 41:101–121CrossRef
33.
Han C, Yang SC (2005) High throughput screening assay and application. Biotechnol Bull 2
34.
35.
36.
Sharma SV, Haber DA, Settleman J (2010) Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 10:241–253CrossRef
37.
Wang H, Wang Q (2014) Application of and prospect for targeted capture with the first generation of sequencing technology in the study of hereditary hearing loss. J Audiol Speech Pathol 5
Metadaten
Titel
Case I: 3DMed: An R&D Platform for Personalised Precision Anti-cancer Drugs
verfasst von
Xiaoming Zhu
Copyright-Jahr
2018
Verlag
Springer Singapore
Buch
China's Technology Innovators

Print ISBN: 978-981-10-5387-0

Electronic ISBN: 978-981-10-5388-7

Copyright-Jahr: 2018

DOI
https://doi.org/10.1007/978-981-10-5388-7_1

Premium Partner

    Bildnachweise